UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

Date of Report: November 2, 2015 Commission File Number: 001-36891

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of principal executive office)

ndicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
ndicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Form 20-F ☑ Form 40-F 🛘
indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

EXHIBIT INDEX

Exhibit <u>Title</u>

99.1 Press release, dated November 2, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.

(Registrant)

November 2, 2015

By: /s/ André Choulika

André Choulika Chief Executive Officer

Calyxt Completes the First Field Trials of Its Cold Storable Potato Product

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--November 2, 2015--Calyxt, Inc., a Minnesota-based company focusing on developing healthier food products to benefit both consumers and farmers, today announced that it has completed the first field trials in Minnesota, Wisconsin and Michigan of its cold storable potato.

A significant amount of potatoes harvested each fall are cold-stored to ensure a continuous supply throughout the year. During cold storage, reducing sugars can accumulate in the potatoes and when cooked at temperatures above 250°F, the reducing sugars interact with free amino acids to form acrylamide. The National Toxicology Program and the International Agency for Research on Cancer considers acrylamide a 'probable' human carcinogen.

Our scientists at Calyxt have inactivated the enzyme responsible for the degradation of sugars in the tuber, thus reducing both the sweetening of cold-stored potatoes and also the creation of acrylamide during frying.

Calyxt has previously validated the effectiveness of its cold-storable potatoes in the greenhouse and the harvest of the multi-location field trials is an important next step for demonstrating the cold-storable trait from field-grown material. In addition to increasing the amount of material to conduct commercial cold storage assays, certified seed production is underway to facilitate a commercial launch.

"We are very pleased by the results of our field trials, that continues to demonstrate Calyxt is an innovated player in the potato industry. Cold-storable, non-transgenic potatoes provide a continuous, high quality supply of potatoes and also increases the usable yield for the French fries, potato chips and fresh market industries," said Dan Voytas, Chief Scientific Officer of Calyxt, Inc.

About Calyxt

Founded in 2010, Calyxt, Inc. (previously Cellectis plant sciences, Inc.) is based in New Brighton, Minnesota (USA). The company aims to create healthier crop products such as low trans fat soybean oil, cold-storable potato, gluten reduced wheat and low saturated fat canola oil for the food and agriculture industries. Calyxt is developing a network of partnerships in order to secure accessibility of its food products to consumers.

For further information please visit our website: www.calyxt.com

Calyxt[™] and the corporate logo are trademarks owned by Calyxt, Inc.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis SA in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

CONTACT:

For further information, please contact:

Media contacts

Jennifer Moore, VP Communications

Phone: 917-580-1088 email: media@cellectis.com

or

Caitlin Kasunich / Dixon Moretz KCSA Strategic Communications 212.896.1241 / 212.896.1251

ckasunich@kcsa.com / dmoretz@kcsa.com

or

Investor Relations contact

Simon Harnest, VP Finance and Investor Relations

Phone: 646-385-9008

email: simon.harnest@cellectis.com